Literature DB >> 33152758

Remdesivir and GS-441524 plasma concentrations in patients with end-stage renal disease on haemodialysis.

Matthew R Davis1, Christine U Pham2, Jeffrey J Cies3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33152758     DOI： 10.1093/jac/dkaa472

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  7 in total

1.  Osmotic Tubulopathy and Acute Thrombotic Microangiopathy in a Kidney Transplant Recipient With a Breakthrough SARS-CoV-2 Infection.

Authors:  Peter Fahim; Anthony Nicolaysen; Julie M Yabu; Jonathan E Zuckerman
Journal:  Kidney Med       Date:  2022-05-26

2.  Plasma concentrations of remdesivir metabolite in a critical COVID-19 patient needing continuous venovenous haemodialysis.

Authors:  Massimo Tempestilli; Giulia Valeria Stazi; Gaetano Maffongelli; Maria Cristina Marini; Tommaso Ascoli Bartoli; Giuseppe Ippolito; Emanuele Nicastri; Luisa Marchioni; Chiara Agrati
Journal:  Eur J Clin Pharmacol       Date:  2021-05-12       Impact factor: 3.064

3.  A Valid Warning or Clinical Lore: an Evaluation of Safety Outcomes of Remdesivir in Patients with Impaired Renal Function from a Multicenter Matched Cohort.

Authors:  Tyler W Ackley; Dayna McManus; Jeffrey E Topal; Brian Cicali; Sunish Shah
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

4.  Therapeutic dilemmas in dialysis patients hospitalized for COVID-19: balancing between nihilism, off-label treatment and side effects.

Authors:  Mariusz Kusztal; Marek Myślak
Journal:  Clin Kidney J       Date:  2021-01-11

5.  Efficacy of remdesivir for hospitalized COVID-19 patients with end stage renal disease.

Authors:  Vijairam Selvaraj; Amos Lal; Arkadiy Finn; Joshua Ray Tanzer; Muhammad Baig; Atin Jindal; Kwame Dapaah-Afriyie; George Bayliss
Journal:  World J Crit Care Med       Date:  2022-01-09

6.  Exploration for the effect of renal function and renal replacement therapy on pharmacokinetics of remdesivir and GS-441524 in patients with COVID-19: A limited case series.

Authors:  Pyoeng Gyun Choe; Sae Im Jeong; Chang Kyung Kang; Liju Yang; SeungHwan Lee; Joo-Youn Cho; Seung Seok Han; Dong Ki Kim; Sang Min Lee; Wan Beom Park; Myoung-Don Oh; Nam Joong Kim
Journal:  Clin Transl Sci       Date:  2021-11-20       Impact factor: 4.438

7.  Co-administration of Favipiravir and the Remdesivir Metabolite GS-441524 Effectively Reduces SARS-CoV-2 Replication in the Lungs of the Syrian Hamster Model.

Authors:  Shiho Chiba; Maki Kiso; Noriko Nakajima; Shun Iida; Tadashi Maemura; Makoto Kuroda; Yuko Sato; Mutsumi Ito; Moe Okuda; Shinya Yamada; Kiyoko Iwatsuki-Horimoto; Tokiko Watanabe; Masaki Imai; Tammy Armbrust; Ralph S Baric; Peter J Halfmann; Tadaki Suzuki; Yoshihiro Kawaoka
Journal:  mBio       Date:  2022-02-01       Impact factor: 7.867
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.